Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
NCT00027482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2017-07-02
Summary
This study will explore the responses of the immune system to infection with HIV and other pathogens and the changes in these responses over time.
Healthy normal volunteers and HIV-infected patients 18 years of age or older may be eligible for this study.
Prior to enrollment and yearly thereafter, vital signs, height and weight will be recorded. A medical history will be obtained if relevant to the laboratory research for which the sample will be used. A more extensive history and physical exam is not required but may be performed if deemed necessary by the VRC clinician. A complete blood count will be performed on the day of enrollment and yearly thereafter. Samples will be collected in the following manner:
Blood will be drawn from a needle in an arm vein one or more times during the course of the study. From 20 to 150 cc (4 to 30 teaspoonfuls) of blood will be collected at a time. No more than 450 cc (less than 1 pint) of blood will be drawn during any 6-week period.
Urine and saliva samples will be collected by the volunteer in private.
Swab samples will be collected by a nurse or doctor, using a cotton swab to brush inside the mouth.
Samples may be used for the following tests:
* Hepatitis and other viral screening-This may include screening for different types of viral liver infections, such as hepatitis A, B, C, D, E, or G; for cytomegalovirus (related to the herpes virus); and for varicella zoster virus (responsible for chicken pox in children and shingles in adults).
* Genetic testing-DNA in blood cells may be examined for genetic mutations (physical or chemical changes) or deletions (missing pieces) that affect substances involved in the body's ability to mount an inflammatory immune response. Alterations in the genes for some of these substances have been shown to influence HIV infection.
* HLA testing-HLA type is a genetic marker of the immune system. Determining HLA type is necessary in order to do certain research studies. Some HLA types have been associated with an increased risk of diseases like arthritis and other rheumatologic problems. HLA testing may be used to try to identify factors associated with the rate of progression of HIV disease or related conditions.
* Other laboratory tests as clinically indicated or required for research needs.
Some samples collected in this study may be stored for future research.They will be labeled without identifying information.
Those with interesting or strongly positive immune responses may be asked to return to the VRC Clinic to provide samples of urine or oral secretions.
Conditions
- Healthy
- HIV Infection
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2001-12-04
- Completion
- 2008-08-27
Countries
- United States
Study Locations
More Related Trials
-
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
NCT00000779 ·Status: COMPLETED ·Phase: PHASE1
-
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
NCT00058734 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials
NCT01376726 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
NCT00001064 ·Status: TERMINATED ·Phase: NA
-
Screening HIV-Infected Patients for Vaccine Studies
NCT00051519 ·Status: COMPLETED
-
Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
NCT01381029 ·Status: COMPLETED
-
Resistance to HIV Infection
NCT00069485 ·Status: UNKNOWN
-
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
NCT00833781 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An HIV Vaccine Preparedness Study
NCT00000915 ·Status: COMPLETED ·Phase: NA
-
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
NCT01386489 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
NCT00000756 ·Status: COMPLETED ·Phase: PHASE1
-
Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
NCT00050284 ·Status: COMPLETED
-
A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
NCT00000852 ·Status: COMPLETED ·Phase: NA
-
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
NCT00238459 ·Status: COMPLETED
-
Selection of a Protective T Cell-based HIV-1/FIV Vaccine
NCT02389595 ·Status: ACTIVE_NOT_RECRUITING
-
Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity
NCT02886416 ·Status: COMPLETED
-
H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients
NCT01111162 ·Status: COMPLETED ·Phase: PHASE4
-
HIV-1 Vaccine Test in Uninfected Adult Volunteers
NCT00047931 ·Status: COMPLETED ·Phase: PHASE1
-
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
NCT00992433 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
NCT00002359 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
NCT00021762 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Anti-HIV Therapy Intensification
NCT00034086 ·Status: COMPLETED ·Phase: NA
-
HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
NCT00056758 ·Status: COMPLETED ·Phase: PHASE1
-
Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
NCT07126652 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)
NCT00001021 ·Status: COMPLETED ·Phase: PHASE1